These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 15161354

  • 1. Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors.
    Hicks KO, Siim BG, Pruijn FB, Wilson WR.
    Radiat Res; 2004 Jun; 161(6):656-66. PubMed ID: 15161354
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.
    Hicks KO, Siim BG, Jaiswal JK, Pruijn FB, Fraser AM, Patel R, Hogg A, Liyanage HD, Dorie MJ, Brown JM, Denny WA, Hay MP, Wilson WR.
    Clin Cancer Res; 2010 Oct 15; 16(20):4946-57. PubMed ID: 20732963
    [Abstract] [Full Text] [Related]

  • 3. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
    Siim BG, Pruijn FB, Sturman JR, Hogg A, Hay MP, Brown JM, Wilson WR.
    Cancer Res; 2004 Jan 15; 64(2):736-42. PubMed ID: 14744792
    [Abstract] [Full Text] [Related]

  • 4. Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures.
    Hicks KO, Pruijn FB, Sturman JR, Denny WA, Wilson WR.
    Cancer Res; 2003 Sep 15; 63(18):5970-7. PubMed ID: 14522924
    [Abstract] [Full Text] [Related]

  • 5. Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model.
    Hicks KO, Fleming Y, Siim BG, Koch CJ, Wilson WR.
    Int J Radiat Oncol Biol Phys; 1998 Oct 01; 42(3):641-9. PubMed ID: 9806526
    [Abstract] [Full Text] [Related]

  • 6. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs.
    Hicks KO, Pruijn FB, Secomb TW, Hay MP, Hsu R, Brown JM, Denny WA, Dewhirst MW, Wilson WR.
    J Natl Cancer Inst; 2006 Aug 16; 98(16):1118-28. PubMed ID: 16912264
    [Abstract] [Full Text] [Related]

  • 7. Regulation of hypoxia-induced mRNA expressions of HIF-1alpha and osteopontin and in vitro radiosensitization by tirapazamine in human nasopharyngeal carcinoma HNE-1 and CNE-1 cells.
    Xu P, Huang JM, Ren Y, Zha X, Deng BF, Wu JH, Lang JY.
    Chin J Cancer; 2010 Feb 16; 29(2):126-30. PubMed ID: 20109337
    [Abstract] [Full Text] [Related]

  • 8. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
    Hicks KO, Myint H, Patterson AV, Pruijn FB, Siim BG, Patel K, Wilson WR.
    Int J Radiat Oncol Biol Phys; 2007 Oct 01; 69(2):560-71. PubMed ID: 17869669
    [Abstract] [Full Text] [Related]

  • 9. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
    Papadopoulou MV, Ji M, Rao MK, Bloomer WD.
    Oncol Res; 2001 Oct 01; 12(8):325-33. PubMed ID: 11589303
    [Abstract] [Full Text] [Related]

  • 10. Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting.
    Delahoussaye YM, Hay MP, Pruijn FB, Denny WA, Brown JM.
    Biochem Pharmacol; 2003 Jun 01; 65(11):1807-15. PubMed ID: 12781332
    [Abstract] [Full Text] [Related]

  • 11. Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity.
    Guise CP, Abbattista MR, Anderson RF, Li D, Taghipouran R, Tsai A, Lee SJ, Smaill JB, Denny WA, Hay MP, Wilson WR, Hicks KO, Patterson AV.
    Molecules; 2020 Oct 22; 25(21):. PubMed ID: 33105798
    [Abstract] [Full Text] [Related]

  • 12. A hybrid cellular automaton model of solid tumor growth and bioreductive drug transport.
    Kazmi N, Hossain MA, Phillips RM.
    IEEE/ACM Trans Comput Biol Bioinform; 2012 Oct 22; 9(6):1595-606. PubMed ID: 23221082
    [Abstract] [Full Text] [Related]

  • 13. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity.
    Elwell JH, Siim BG, Evans JW, Brown JM.
    Biochem Pharmacol; 1997 Jul 15; 54(2):249-57. PubMed ID: 9271329
    [Abstract] [Full Text] [Related]

  • 14. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model.
    Kyle AH, Minchinton AI.
    Cancer Chemother Pharmacol; 1999 Jul 15; 43(3):213-20. PubMed ID: 9923551
    [Abstract] [Full Text] [Related]

  • 15. Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures.
    Pruijn FB, Sturman JR, Liyanage HD, Hicks KO, Hay MP, Wilson WR.
    J Med Chem; 2005 Feb 24; 48(4):1079-87. PubMed ID: 15715475
    [Abstract] [Full Text] [Related]

  • 16. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.
    Saunders MP, Patterson AV, Chinje EC, Harris AL, Stratford IJ.
    Br J Cancer; 2000 Feb 24; 82(3):651-6. PubMed ID: 10682679
    [Abstract] [Full Text] [Related]

  • 17. Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine.
    Yang B, Keshelava N, Anderson CP, Reynolds CP.
    Cancer Res; 2003 Apr 01; 63(7):1520-6. PubMed ID: 12670899
    [Abstract] [Full Text] [Related]

  • 18. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia.
    Siim BG, Menke DR, Dorie MJ, Brown JM.
    Cancer Res; 1997 Jul 15; 57(14):2922-8. PubMed ID: 9230202
    [Abstract] [Full Text] [Related]

  • 19. DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.
    Hay MP, Pruijn FB, Gamage SA, Liyanage HD, Kovacs MS, Patterson AV, Wilson WR, Brown JM, Denny WA.
    J Med Chem; 2004 Jan 15; 47(2):475-88. PubMed ID: 14711317
    [Abstract] [Full Text] [Related]

  • 20. DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine.
    Dorie MJ, Kovacs MS, Gabalski EC, Adam M, Le QT, Bloch DA, Pinto HA, Terris DJ, Brown JM.
    Neoplasia; 1999 Nov 15; 1(5):461-7. PubMed ID: 10933062
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.